Novartis India Signs ₹10 Crore Exclusive Agreement For Retina Portfolio

Novartis India secured exclusive Indian promotion and distribution rights for NHPL’s retina products Accentrix and Pagenax, supporting entry into ophthalmology, for an upfront payment of ₹10 crore. Context: first entry into a new therapy area.